Naveen Reddy, MD
Pain Medicine · Chandler, AZNPI 1003875451
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,400 of the $3,271 with a category attached, or 73.4%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 73.4% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2021 at $2,417 and has fallen 95.8% since, to $103 in 2025. That places this record below the midpoint for pain medicine clinicians in AZ, where the typical reported total is $3,853.
Across 33 payments — averaging $99.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Abbott$601
- Nevro Corp.$103
- Averitas Pharma Inc.$51
- Globus Medical$32
- Relievant Medsystems, Inc.$29
- plus $56 from 3 others
What the payments were for
- Consulting fees$2,40073%
- Food & beverage$87127%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $2,400 |
| Abbott | 18 | $601 |
| Nevro Corp. | 5 | $103 |
| Averitas Pharma Inc. | 2 | $51 |
| Globus Medical | 2 | $32 |
| Relievant Medsystems, Inc. | 1 | $29 |
| Novartis | 2 | $25 |
| SPR Therapeutics, Inc | 1 | $17 |
| Bioventus LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,271 in reported general payments places this provider in the 45th percentile of 180 pain medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 15 | $8,219 |
| Gabapentin | 185 | $2,946 |
| Morphine Sulfate ErMorphine Sulfate | 59 | $1,951 |
| Pregabalin | 85 | $1,908 |
| Duloxetine Hcl | 69 | $1,542 |
| Tramadol Hcl | 156 | $1,044 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 99 | $918 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 54 | $721 |
| Tizanidine Hcl | 15 | $414 |
| Oxycodone Hcl | 28 | $286 |
| Cyclobenzaprine Hcl | 34 | $200 |
| Morphine Sulfate | 14 | $96 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Chandler
- Tristan PicoChandler$121K
- Stuart RammellChandler$24K
- Eric CornidezTucson$496K
- Tory McJunkinScottsdale$204K
- Minesh ZaveriPhoenix$187K
- Chad PletnickOro Valley$137K
- Selaiman NooriLake Havasu City$104K
- Christine HaddadPhoenix$98K
- Samir PatelOro Valley$70K
- Vivek IyerScottsdale$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.